...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study

Bear, your answer lies in the ERA-EDTA presentation. Slide 17.

CKD patients had a longer mean duration of diabetes (11.3 vs. 8.2 years, P<0.001) and were less likely to be treated with metformin (69% vs. 84%, P<0.001) and SGLT2 inhibitors (6% vs. 13%, P=0.001)

https://www.resverlogix.com/upload/event/51/f774c8cb90f0/zadeh-eraedta-presentation---rvx-website-2020-06-08.pdf

I think its a good news, but we should ask the question about DPP4i's too.

 

Share
New Message
Please login to post a reply